MEK inhibition significantly decreased tumor growth in all of the MPNST lines, yet substantial response heterogeneity was observed in the NF1-MET and NF1-P53 tumors (Figure 2A–C) [6]. This evidence concerns the gene MAP2K7 and malignant peripheral nerve sheath tumor.